Literature DB >> 24434204

RAS's cloak of invincibility slips at last?

Julian Downward1.   

Abstract

KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts to inhibit its function directly. However, a recent report provides an entirely new approach to blocking mutant KRAS with small molecules and has the added benefit of sparing the wild-type protein.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Year:  2014        PMID： 24434204     DOI： 10.1016/j.ccr.2013.12.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  On human disease-causing amino acid variants: statistical study of sequence and structural patterns.

Authors:  Marharyta Petukh; Tugba G Kucukkal; Emil Alexov
Journal:  Hum Mutat       Date:  2015-04-06       Impact factor: 4.878

2.  Phosphorylation of the C-Raf N Region Promotes Raf Dimerization.

Authors:  Maho Takahashi; Yanping Li; Tara J Dillon; Yumi Kariya; Philip J S Stork
Journal:  Mol Cell Biol       Date:  2017-09-12       Impact factor: 4.272

Review 3.  Targeting Mutated KRAS Genes to Treat Solid Tumours.

Authors:  Tharani Krishnan; Rachel Roberts-Thomson; Vy Broadbridge; Timothy Price
Journal:  Mol Diagn Ther       Date:  2021-12-16       Impact factor: 4.074

Review 4.  RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Authors:  Julian Downward
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

5.  The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.

Authors:  Shaoyong Lu; Hyunbum Jang; Ruth Nussinov; Jian Zhang
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

6.  Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation.

Authors:  Jae-Hyun Jang; Donghwan Park; Guen-Soo Park; Dong-Wook Kwak; JaeIn Park; Dae-Yeul Yu; Hye Jin You; Jae-Hong Kim
Journal:  Exp Mol Med       Date:  2021-10-11       Impact factor: 8.718

7.  KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor.

Authors:  Nandie Wu; Ying Huang; Fangcen Liu; Xingyun Xu; Baorui Liu; Jia Wei
Journal:  J Gastrointest Oncol       Date:  2021-06

8.  An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors.

Authors:  Rasmus Hansen; Sarah J Firdaus; Shuangwei Li; Matthew R Janes; Jingchuan Zhang; Yi Liu; Patrick P Zarrinkar
Journal:  Sci Rep       Date:  2018-09-25       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.